2021
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2017
Antipsychotics for aggression in adults: A meta-analysis
van Schalkwyk GI, Beyer C, Johnson J, Deal M, Bloch MH. Antipsychotics for aggression in adults: A meta-analysis. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2017, 81: 452-458. PMID: 28754408, DOI: 10.1016/j.pnpbp.2017.07.019.Peer-Reviewed Original ResearchConceptsTreatment of aggressionAntipsychotic medicationNon-pharmacologic interventionsEffect sizeChoice of agentSignificant dose effectSignificant morbidityCochrane LibraryAntipsychotic agentsDopamine antagonistsPsychiatric illnessIrritable moodMultiple diagnosesClinical decisionAntipsychoticsSpecific agentsSearch termsSmall effect sizesDiagnosisDose effectMedicationsSymptom dimensionsAggressive behaviorTreatmentAdults